Isotretinoin may affect pharmacokinetics of itraconazole in the skin: Is it rational to combine both for the treatment of dermatophytosis?

Sir,

This is in reference to the therapy letter, “Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole” published in your esteemed journal.1 We read this article with great interest and would like to consider retinoids as another armamentarium to deal with the current menace of dermatophytosis. We do agree with the role of isotretinoin in dermatophytosis as an individual agent, based on its properties as suggested by the authors such as keratolytic effect (resulting in elimination of dermatophytes), increase in skin pH and boosting of humoral and cellular immunity. However, there are some points that need to be explored further to assess the efficacy of itraconazole and isotretinoin combination based on the pharmacokinetic properties of itraconazole.

After oral administration, itraconazole is delivered to the epidermis through passive uptake by keratinocytes in the basal layer and by secretion into sebum and sweat.2 Tissue levels of itraconazole are 3–20-fold higher than plasma concentration and it persists in the stratum corneum for 3 weeks after stopping therapy, thereby demonstrating a ‘reservoir effect’ which prevents recurrence of dermatophytosis.3-5 The drug is eliminated from the body along with shedding of the stratum corneum during the process of epidermal turnover. Since isotretinoin affects epidermal cell kinetics and increases cell turnover, it is likely that coadministration of isotretinoin and itraconazole would result in a rapid clearance of itraconazole from the skin. In this way, isotretinoin can lead to decreased reservoir effect. A similar effect is expected in nails too as retinoids promote nail growth.

Second, itraconazole is a highly lipophilic drug, thus it achieves high levels in sebum.2 This is in contrast to other azole antifungals such as ketoconazole (which is secreted predominantly in sweat). Sebum levels of itraconazole are five to ten times higher than the corresponding plasma levels while secretion in sweat does not play a major role in delivery of itraconazole to the stratum corneum.6 Clinically, it results in need of higher doses required for the treatment of palmar and plantar dermatophytic infections, due to the absence of sebaceous glands at these sites.7 Again, since isotretinoin decreases sebum production considerably, it can lead to decreased therapeutic efficacy of itraconazole.

Furthermore, as it is reported in this particular case, we would also like to comment that initially both oral as well as topical antifungal drugs were given for 2 weeks only and then the drugs were changed. This could have resulted in inadequate duration of therapy, thereby resulting in relapse of lesions and poor response to therapy.

Therefore, we would like to suggest that adequate studies focusing on the effect of isotretinoin on pharmacokinetics of itraconazole, i.e., difference in the level of drug persisting in the stratum corneum and sebum with and without combining isotretinoin should be carried out to further substantiate the role of adding oral retinoids to antifungal therapy.

Conflicts of interest
There are no conflicts of interest.

Financial support and sponsorship
Nil.

Ankita Srivastava, Sunil Kumar Kothiwala
Department of Dermatology and Venereology, Jaipur National University Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan, India

Address for correspondence: Dr. Sunil Kumar Kothiwala, Department of Dermatology and Venereology, Jaipur National University Institute for Medical Sciences and Research Centre, Jaipur, Rajasthan, India. E-mail: drsunilkothiwala.aiims@gmail.com
REFERENCES

1. Ardeshna KP, Rohatgi S, Jerajani HR. Successful treatment of recurrent dermatophytosis with isotretinoin and itraconazole. Indian J Dermatol Venereol Leprol 2016;82:579-82.

2. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haevermans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988;18(2 Pt 1):263-8.

3. Heykants J, Van Peer A, Van de Velde V, Van Rooy P, Meuldermans W, Lavrijsen K, et al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989;32 Suppl 1:67-87.

4. Negroni R, Arechavala AI. Itraconazole: Pharmacokinetics and indications. Arch Med Res 1993;24:387-93.

5. Del Rosso JQ, Gupta AK. The use of intermittent itraconazole therapy for superficial mycotic infections: A review and update on the ‘one week’ approach. Int J Dermatol 1999;38 Suppl 2:28-39.

6. Cauwenbergh G. Skin kinetics of azole antifungal drugs. In: Borgers M, Hay R, Rinaldi MG, editors. Current Topics in Medical Mycology. 1st ed. New York: Springer-Verlag; 1992. p. 88-136.

Author’s reply

Sir,

We thank the authors for showing interest in our paper and accepting our arguments justifying the use of isotretinoin in dermatophytosis. While there are concerns on the rationality of this combination, we want to highlight yet again that the use of this combination should only be reserved for recalcitrant cases.

It is likely that the increased cell turnover brought about by isotretinoin may result in faster clearance of itraconazole from the skin, thereby also reducing the reservoir effect. However, the argument put forward by the authors is based on concentration of any drug in isolation is of limited value and should ideally be analyzed along with concomitant pharmacodynamic data. For example, amphotericin B deoxycholate and itraconazole have low concentrations in the cerebrospinal fluid yet they are effective agents for the treatment of cryptococcal meningitis. Tissue homogenates are frequently used to estimate tissue concentrations but they are a relatively crude and potentially misleading matrix when used for this purpose. Mouton et al. have highlighted the potential pitfalls in using drug concentrations within whole-tissue homogenates for drawing conclusions related to the activity and efficacy of a drug, especially for extracellular pathogens. Moreover, studies trying to correlate in vitro dermatophyte minimal inhibitory concentrations with clinical outcomes have often failed to produce definitive results. Despite our counterargument, we agree that further in-depth studies are required to evaluate the effect of isotretinoin on pharmacokinetics and pharmacodynamics of itraconazole.

Since isotretinoin decreases sebum production and sebum being a major route of delivery of itraconazole to the stratum corneum, it can possibly reduce the bioavailability of the drug to infected sites. Our first argument holds valid for this query as well. We do not know much about the impact of isotretinoin on the pharmacokinetics of itraconazole although it is plausible theoretically.

The final query was regarding inadequate duration of therapy resulting in poor response and possible relapse. We agree that continuing the same oral antifungal for longer period might have given better result. However, according to literature and dermatology textbooks, the recommended dose and duration of treatment for tinea cruris/corporis with oral itraconazole is 100 mg/day for 2 weeks or 200 mg/day for 1 week. In fact, this duration is also advocated in the package insert of itraconazole (Sporanox ®). We used the same regimen for our patient; nevertheless considering the present scenario of relapsing dermatophytosis in our country, longer treatment schedule may be required.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

How to cite this article: Srivastava A, Kothiwal SK. Isotretinoin may affect pharmacokinetics of itraconazole in the skin: Is it rational to combine both for the treatment of dermatophytosis?. Indian J Dermatol Venereol Leprol 2017;83:68-9.

Received: August, 2016. Accepted: October, 2016.